What is Until Labs?
Until Labs is at the forefront of developing technology designed to pause biological time. The company leverages an in-house multidisciplinary team of biologists, engineers, and physicists to prototype and scale advanced cryopreservation methods. This innovative approach aims to address critical challenges in areas such as organ transplantation, long-term medical storage, and potentially extending the viability of biological materials.
How much funding has Until Labs raised?
Until Labs has raised a total of $58M across 1 funding round:
Series A
$58M
Series A (2025): $58M with participation from Founders Fund and Lux Capital
Key Investors in Until Labs
Founders Fund
Founders Fund is a venture capital firm known for investing in transformative companies across various sectors, with a history of backing influential tech giants.
Lux Capital
Lux Capital is a venture capital firm focused on investing in early-stage and growth-stage companies at the intersection of science and technology, including AI, robotics, space, and biotechnology.
What's next for Until Labs?
With this substantial enterprise-level funding, Until Labs is poised for significant expansion and acceleration of its research and development initiatives. The strategic investment will likely fuel the scaling of their cryopreservation technologies, further refine their prototyping processes, and potentially enable clinical trials or broader application testing. This capital infusion signals a strong market belief in Until Labs' potential to disrupt the field of biological preservation and achieve its ambitious goals.
See full Until Labs company page
